Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of May 2021, with a specific reporting date of May 13, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| May 12, 2021 | Ordinary Shares (25p each) | £13.407 | 18 to 20 shares per individual | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It details routine acquisitions of ordinary shares by senior executives as part of a compensation plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed under the Company's Share Reward Plan, involving both partnership shares and matching shares.
Investor Verification Checklist
- Verify the total number of shares acquired by each listed executive to ensure compliance with internal trading policies.
- Confirm the transaction price of £13.407 aligns with the market price on the London Stock Exchange for May 12, 2021.
- Review the full list of PDMRs and PCAs involved to assess concentration of insider holdings.
- Note that this filing provides no data on GSK's operational performance or financial health for the period.